These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 17596833)

  • 1. Hepatitis C virus expression and interferon antiviral action is dependent on PKR expression.
    Tokumoto Y; Hiasa Y; Horiike N; Michitaka K; Matsuura B; Chung RT; Onji M
    J Med Virol; 2007 Aug; 79(8):1120-7. PubMed ID: 17596833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.
    Liu WL; Su WC; Cheng CW; Hwang LH; Wang CC; Chen HL; Chen DS; Lai MY
    J Infect Dis; 2007 Aug; 196(3):425-34. PubMed ID: 17597457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
    Chang JH; Kato N; Muroyama R; Taniguchi H; Guleng B; Dharel N; Shao RX; Tateishi K; Jazag A; Kawabe T; Omata M
    Liver Int; 2010 Feb; 30(2):311-8. PubMed ID: 19840259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferons specifically suppress the translation from the internal ribosome entry site of hepatitis C virus through a double-stranded RNA-activated protein kinase-independent pathway.
    Kato J; Kato N; Moriyama M; Goto T; Taniguchi H; Shiratori Y; Omata M
    J Infect Dis; 2002 Jul; 186(2):155-63. PubMed ID: 12134250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control.
    Kang JI; Kwon SN; Park SH; Kim YK; Choi SY; Kim JP; Ahn BY
    Virus Res; 2009 Jun; 142(1-2):51-6. PubMed ID: 19189853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis.
    François C; Duverlie G; Rebouillat D; Khorsi H; Castelain S; Blum HE; Gatignol A; Wychowski C; Moradpour D; Meurs EF
    J Virol; 2000 Jun; 74(12):5587-96. PubMed ID: 10823866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication.
    Itsui Y; Sakamoto N; Kurosaki M; Kanazawa N; Tanabe Y; Koyama T; Takeda Y; Nakagawa M; Kakinuma S; Sekine Y; Maekawa S; Enomoto N; Watanabe M
    J Viral Hepat; 2006 Oct; 13(10):690-700. PubMed ID: 16970601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells.
    Alisi A; Mele R; Spaziani A; Tavolaro S; Palescandolo E; Balsano C
    J Cell Physiol; 2005 Oct; 205(1):25-31. PubMed ID: 15880455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR.
    Yan XB; Battaglia S; Boucreux D; Chen Z; Brechot C; Pavio N
    Virus Res; 2007 Apr; 125(1):79-87. PubMed ID: 17267064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.
    Murao K; Imachi H; Yu X; Cao WM; Nishiuchi T; Chen K; Li J; Ahmed RA; Wong NC; Ishida T
    Gut; 2008 May; 57(5):664-71. PubMed ID: 17998316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.
    Buckwold VE; Wei J; Huang Z; Huang C; Nalca A; Wells J; Russell J; Collins B; Ptak R; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
    Antiviral Res; 2007 Feb; 73(2):118-25. PubMed ID: 16987555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
    Xu J; Liu S; Xu Y; Tien P; Gao G
    Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics.
    Lanford RE; Guerra B; Lee H; Chavez D; Brasky KM; Bigger CB
    Hepatology; 2006 May; 43(5):961-72. PubMed ID: 16628626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells.
    Naka K; Abe K; Takemoto K; Dansako H; Ikeda M; Shimotohno K; Kato N
    J Hepatol; 2006 May; 44(5):869-78. PubMed ID: 16545484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational insensitivity to potent activation of PKR by HCV IRES RNA.
    Shimoike T; McKenna SA; Lindhout DA; Puglisi JD
    Antiviral Res; 2009 Sep; 83(3):228-37. PubMed ID: 19467267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cell-based bicistronic lentiviral reporter system for identification of inhibitors of the hepatitis C virus internal ribosome entry site.
    Lourenço S; Boni S; Furling D; Cosset FL; Cahour A
    J Virol Methods; 2009 Jun; 158(1-2):152-9. PubMed ID: 19428584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of PI3K in HCV-related lymphoproliferative disorders.
    Alisi A; Giannini C; Spaziani A; Caini P; Zignego AL; Balsano C
    J Cell Physiol; 2008 Feb; 214(2):396-404. PubMed ID: 17654494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment.
    Urbani S; Amadei B; Tola D; Pedrazzi G; Sacchelli L; Cavallo MC; Orlandini A; Missale G; Ferrari C
    J Hepatol; 2008 Apr; 48(4):548-58. PubMed ID: 18280607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents.
    Nishimura G; Ikeda M; Mori K; Nakazawa T; Ariumi Y; Dansako H; Kato N
    Antiviral Res; 2009 Apr; 82(1):42-50. PubMed ID: 19428594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.